LiverMultiScan logo

LiverMultiScan

Noninvasive MRI assessment of liver disease with quantitative biomarkers for diagnosis, stratification, and treatment monitoring.

Solution by Perspectum
Visit website

Overview

LiverMultiScan, developed by Perspectum, is a noninvasive multiparametric MRI scan designed to accurately assess signs of liver disease and provide a comprehensive picture of liver health. It is intended for healthcare professionals seeking a safe, accurate, and cost-effective alternative to liver biopsy for the diagnosis, stratification, and monitoring of metabolic and chronic liver diseases, including MASLD, MASH, and other chronic liver conditions (CLD).

LiverMultiScan delivers quantitative, standardized biomarkers — most notably corrected T1 (cT1) and proton density fat fraction (PDFF) — that correlate with histopathological biopsy features such as NAS score and fibrosis stage. The scan requires no contrast agent, needles, or radiation exposure, and is completed in approximately five minutes, making it a practical and patient-friendly clinical tool with nationwide payor coverage in the United States.

Clinical Performance and Diagnostic Accuracy

  • Recognized as best-in-class and a viable alternative to liver biopsy for the detection and stratification of MASH
  • Outperforms other noninvasive tests in MASH detection and patient stratification
  • Correlates with biopsy features including NAS score and fibrosis stage
  • Demonstrates lower failure rates compared to elastography, even in patients with high BMI
  • More robust than competing tests across MASLD, MASH, and CLD patient populations
  • Avoids the risk of complications associated with invasive liver biopsy
  • Detects change more reliably than competing noninvasive methods

Prognostic Value

  • Predicts both major liver-related and cardiovascular outcomes in patients with chronic liver disease
  • High cT1 values are linked to cardiovascular disease (CVD) events and mortality
  • Predicts CVD hospitalisation in population cohorts where PDFF and FIB-4 do not
  • Supports broader risk stratification beyond liver disease alone
  • Backed by peer-reviewed publications in journals including Nature Medicine, Liver International, and JHEP Reports

Cost-Effectiveness

  • cT1-based care pathways deliver the lowest per-patient cost compared to liver biopsy or FibroScan (VCTE)
  • Reduces the need for specialist visits, biopsies, and additional imaging procedures, streamlining the patient pathway
  • Demonstrated favorable cost-effectiveness with an ICER of approximately €4,900 per QALY across multiple healthcare systems
  • Minimizes complication costs and improves patient safety versus invasive procedures
  • Supports scalable adoption of noninvasive liver assessment within constrained healthcare budgets

Accuracy and Treatment Monitoring

  • A single scan provides a comprehensive liver assessment with accurate, repeatable quantitative data
  • Enables timely clinical intervention and personalized, preventative treatment planning
  • Identifies MASH patients who are eligible for treatment
  • Standardized, reproducible, and repeatable metrics ensure consistent results across sites and time points
  • Changes in cT1 and liver fat content have been shown to reflect histological improvement induced by therapies in MASH

Technical Specifications and Workflow

  • Approved for use on Siemens, GE, and Philips MRI machines at both 1.5 and 3 Tesla field strengths
  • Requires no specialist hardware or software installation — uses existing manufacturer software with only configuration needed to establish a suitable LiverMultiScan sequence
  • Contrast-free scan with an acquisition time of approximately five minutes; can be combined with other protocols if used prior to contrast administration
  • Leverages existing DICOM image exchange platforms for automated data transfer, with native support for Ambra, Powershare, and many other established platforms
  • Results are presented in intuitive, patient-centric reports that are easy to interpret for both clinicians and patients

LiverMultiScan is hosted across several US data centers, enabling data storage and processing to remain within the originating region. Perspectum maintains ISO 27001 information security certification to ensure data safety and security. UK and EU hosting options are also available. Supporting resources including interpretation guides, training manuals, clinical summaries, and promotional materials are available for MRI technicians, healthcare professionals, and patients.

Meta

Domain
Digital Pathology & Imaging
Subdomain
Tissue Biomarker Quantification
Software type(s)
Analytical Platform
Deployment type(s)
Cloud / SaaS
Industry vertical(s)
Academic / ResearchBiotechDiagnostics / IVDPharma
Development stage(s)
ClinicalPost-Market & RWE
Target user(s)
Research ScientistClinical / Diagnostic Professional
Compliance standard(s)
ISO 27001